Barriers to biosimilar prescribing incentives in the context of clinical governance in Spain

e-Archivo Repository

Show simple item record

dc.contributor.author Lobo, Félix
dc.contributor.author Río-Álvarez, Isabel
dc.date.accessioned 2021-10-05T10:10:15Z
dc.date.available 2021-10-05T10:10:15Z
dc.date.issued 2021-03
dc.identifier.bibliographicCitation Lobo, F. & Río-Álvarez, I. (2021). Barriers to Biosimilar Prescribing Incentives in the Context of Clinical Governance in Spain. Pharmaceuticals, 14(3), 283.
dc.identifier.issn 1424-8247
dc.identifier.uri http://hdl.handle.net/10016/33366
dc.description This article belongs to the Special Issue Biosimilars in Europe.
dc.description.abstract Incentives contribute to the proper functioning of the broader contracts that regulate the relationships between health systems and professionals. Likewise, incentives are an important element of clinical governance understood as health services’ management at the micro-level, aimed at achieving better health outcomes for patients. In Spain, monetary and non-monetary incentives are sometimes used in the health services, but not as frequently as in other countries. There are already several examples in European countries of initiatives searching the promotion of biosimilars through different sorts of incentives, but not in Spain. Hence, this paper is aimed at identifying the barriers that incentives to prescribe biosimilars might encounter in Spain, with particular interest in incentives in the framework of clinical governance. Both questions are intertwined. Barriers are presented from two perspectives. Firstly, based on the nature of the barrier: (i) the payment system for health professionals, (ii) budget rigidity and excessive bureaucracy, (iii) little autonomy in the management of human resources (iv) lack of clinical integration, (v) absence of a legal framework for clinical governance, and (vi) other governance-related barriers. The second perspective is based on the stakeholders involved: (i) gaps in knowledge among physicians, (ii) misinformation and distrust among patients, (iii) trade unions opposition to productivity-related payments, (iv) lack of a clear position by professional associations, and (v) misalignment of the goals pursued by some healthcare professionals and the goals of the public system. Finally, the authors advance several recommendations to overcome these barriers at the national level.
dc.description.sponsorship The broader study from which this article is extracted was funded by The Spanish Biosimilar Medicines Association, BioSim.
dc.format.extent 15
dc.language.iso eng
dc.publisher MDPI
dc.rights © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
dc.rights Atribución 3.0 España
dc.rights.uri http://creativecommons.org/licenses/by/3.0/es/
dc.subject.other Barriers
dc.subject.other Biosimilars
dc.subject.other Clinical governance
dc.subject.other Incentives
dc.subject.other Spain
dc.title Barriers to biosimilar prescribing incentives in the context of clinical governance in Spain
dc.type article
dc.subject.eciencia Economía
dc.identifier.doi https://doi.org/10.3390/ph14030283
dc.rights.accessRights openAccess
dc.type.version publishedVersion
dc.identifier.publicationfirstpage 283
dc.identifier.publicationissue 3
dc.identifier.publicationtitle Pharmaceuticals
dc.identifier.publicationvolume 14
dc.identifier.uxxi AR/0000028305
 Find Full text

Files in this item

*Click on file's image for preview. (Embargoed files's preview is not supported)


The following license files are associated with this item:

This item appears in the following Collection(s)

Show simple item record